These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 11457560)
21. Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunteers. Rubinstein A; Goldstein H; Pettoello-Mantovani M; Mizrachi Y; Bloom BR; Furer E; Althaus B; Que JU; Hasler T; Cryz SJ AIDS; 1995 Mar; 9(3):243-51. PubMed ID: 7755912 [TBL] [Abstract][Full Text] [Related]
22. CpG oligodeoxynucleotide and montanide ISA 206 adjuvant combination augments the immune responses of a recombinant FMDV vaccine in cattle. Ren J; Yang L; Xu H; Zhang Y; Wan M; Liu G; Zhao L; Wang L; Yu Y Vaccine; 2011 Oct; 29(45):7960-5. PubMed ID: 21872635 [TBL] [Abstract][Full Text] [Related]
23. Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant. Xue X; Ding F; Zhang Q; Pan X; Qu L; Pan W Vaccine; 2010 Apr; 28(18):3152-8. PubMed ID: 20197139 [TBL] [Abstract][Full Text] [Related]
24. Preformulation study of the vaccine candidate TAB9 against HIV-1. Expósito Raya N; García Díaz A; Carrazana López Y; Quintana Vazquez D; Pichardo Díaz D; Martínez de la Puente N; Duarte Cano C Biotechnol Appl Biochem; 2002 Oct; 36(2):149-53. PubMed ID: 12241557 [TBL] [Abstract][Full Text] [Related]
25. Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors. Bekaii-Saab T; Wesolowski R; Ahn DH; Wu C; Mortazavi A; Lustberg M; Ramaswamy B; Fowler J; Wei L; Overholser J; Kaumaya PTP Clin Cancer Res; 2019 Jun; 25(12):3495-3507. PubMed ID: 30804020 [TBL] [Abstract][Full Text] [Related]
26. Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial. van Doorn E; Pleguezuelos O; Liu H; Fernandez A; Bannister R; Stoloff G; Oftung F; Norley S; Huckriede A; Frijlink HW; Hak E BMC Infect Dis; 2017 Apr; 17(1):241. PubMed ID: 28376743 [TBL] [Abstract][Full Text] [Related]
27. Broadly reactive antibodies against a gp120 V3 loop multi-epitope polypeptide neutralize different isolates of human immunodeficiency virus type 1 (HIV-1). Montero M; Menéndez A; Domínguez MC; Navea L; Vilarubia OL; Quintana D; Izquierdo M; Jiménez V; Reyes O; Lobaina L; Noa E; Duarte CA Vaccine; 1997 Aug; 15(11):1200-8. PubMed ID: 9286044 [TBL] [Abstract][Full Text] [Related]
28. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. Chianese-Bullock KA; Pressley J; Garbee C; Hibbitts S; Murphy C; Yamshchikov G; Petroni GR; Bissonette EA; Neese PY; Grosh WW; Merrill P; Fink R; Woodson EM; Wiernasz CJ; Patterson JW; Slingluff CL J Immunol; 2005 Mar; 174(5):3080-6. PubMed ID: 15728523 [TBL] [Abstract][Full Text] [Related]
29. Candidate multi-epitope vaccines in aluminium adjuvant induce high levels of antibodies with predefined multi-epitope specificity against HIV-1. Ding J; Lu Y; Chen Y FEMS Immunol Med Microbiol; 2000 Oct; 29(2):123-7. PubMed ID: 11024351 [TBL] [Abstract][Full Text] [Related]
30. Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection. Kelleher AD; Emery S; Cunningham P; Duncombe C; Carr A; Golding H; Forde S; Hudson J; Roggensack M; Forrest BD; Cooper DA AIDS Res Hum Retroviruses; 1997 Jan; 13(1):29-32. PubMed ID: 8989424 [TBL] [Abstract][Full Text] [Related]
31. A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. Gorse GJ; Keefer MC; Belshe RB; Matthews TJ; Forrest BD; Hsieh RH; Koff WC; Hanson CV; Dolin R; Weinhold KJ; Frey SE; Ketter N; Fast PE J Infect Dis; 1996 Feb; 173(2):330-9. PubMed ID: 8568293 [TBL] [Abstract][Full Text] [Related]
32. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. Kahn JO; Sinangil F; Baenziger J; Murcar N; Wynne D; Coleman RL; Steimer KS; Dekker CL; Chernoff D J Infect Dis; 1994 Nov; 170(5):1288-91. PubMed ID: 7963729 [TBL] [Abstract][Full Text] [Related]
33. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Goepfert PA; Tomaras GD; Horton H; Montefiori D; Ferrari G; Deers M; Voss G; Koutsoukos M; Pedneault L; Vandepapeliere P; McElrath MJ; Spearman P; Fuchs JD; Koblin BA; Blattner WA; Frey S; Baden LR; Harro C; Evans T; Vaccine; 2007 Jan; 25(3):510-8. PubMed ID: 17049679 [TBL] [Abstract][Full Text] [Related]
34. Safety and tolerability evaluation of the use of Montanide ISA™51 as vaccine adjuvant: A systematic review. van Doorn E; Liu H; Huckriede A; Hak E Hum Vaccin Immunother; 2016; 12(1):159-69. PubMed ID: 26378866 [TBL] [Abstract][Full Text] [Related]
35. Formulation and characterization of a ten-peptide single-vial vaccine, EP-2101, designed to induce cytotoxic T-lymphocyte responses for cancer immunotherapy. Beebe M; Qin M; Moi M; Wu S; Heiati H; Walker L; Newman M; Fikes J; Ishioka GY Hum Vaccin; 2008; 4(3):210-8. PubMed ID: 18382135 [TBL] [Abstract][Full Text] [Related]
36. Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine. Schwartz DH; Gorse G; Clements ML; Belshe R; Izu A; Duliege AM; Berman P; Twaddell T; Stablein D; Sposto R Lancet; 1993 Jul; 342(8863):69-73. PubMed ID: 8100910 [TBL] [Abstract][Full Text] [Related]
37. Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis. Elliott SL; Suhrbier A; Miles JJ; Lawrence G; Pye SJ; Le TT; Rosenstengel A; Nguyen T; Allworth A; Burrows SR; Cox J; Pye D; Moss DJ; Bharadwaj M J Virol; 2008 Feb; 82(3):1448-57. PubMed ID: 18032491 [TBL] [Abstract][Full Text] [Related]
38. Antigenicity and predefined specificities of the multi-epitope vaccine in candidate consisting of neutralizing epitope and mutated epitopes suggested a new way against HIV-1 mutation. Tian H; Xiao Y; Qin L; Chen YH Immunobiology; 2001 Dec; 204(4):434-41. PubMed ID: 11776398 [TBL] [Abstract][Full Text] [Related]
39. Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations. Miles AP; McClellan HA; Rausch KM; Zhu D; Whitmore MD; Singh S; Martin LB; Wu Y; Giersing BK; Stowers AW; Long CA; Saul A Vaccine; 2005 Mar; 23(19):2530-9. PubMed ID: 15752840 [TBL] [Abstract][Full Text] [Related]
40. Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice. Mata E; Carcaboso AM; Hernández RM; Igartua M; Corradin G; Pedraz JL Vaccine; 2007 Jan; 25(5):877-85. PubMed ID: 17070628 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]